TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01059929
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
Study: NCT01111994
Drug: Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
Study: NCT00251004
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral, bis in diem/twice a day (bid)
Study: NCT02737072
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT00251004
Drug: Cyclosporine A (CsA)
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA dose adjustments were based on CsA trough levels (C0).
Study: NCT00251004
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
Study: NCT02360124
Drug: silver diammine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical application of the SDF solution onto tooth root surfaces
Study: NCT04056897
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
Study: NCT00266877
Drug: HKI-272
Normalized name: HKI-357
DrugBank: HKI-357 (DB13002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Study: NCT02508298
Drug: Indocyanine Green Retention test
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As decribed in arm descriptions
Study: NCT00427401
Drug: PF-00915275
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01174238
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
Study: NCT06047184
Drug: BEBT-209 capsules
Normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
Study: NCT06047184
Drug: Letrozole tablets
Normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
Study: NCT06047184
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
Study: NCT01174238
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
Study: NCT01174238
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
Study: NCT02456662
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
Study: NCT04489888
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
Study: NCT04489888
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
Study: NCT04489888
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
Study: NCT04241185
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
Study: NCT04241185
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
Study: NCT04066764
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
Study: NCT04066764
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
Study: NCT04241185
Drug: Mitomycin C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
Study: NCT04241185
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
Study: NCT04241185
Drug: Placebo to Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
Study: NCT04066764
Drug: Nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
Study: NCT01847807
Drug: high dose astagalus
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03181763
Drug: Midomafetamine
Normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 100 mg midomafetamine HCl on their second visit
Study: NCT04382404
Drug: Sofosbuvir-Velpatasvir Drug Combination
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One oral pill containing 400mg sofosbuvir and 100mg velpatasvir taken once daily for 12 weeks
Study: NCT03149848
Drug: Cabotegravir
Normalized name: cabotegravir
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
Study: NCT03149848
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
Study: NCT01244490
Drug: Extended-release Guanfacine Hydrochloride
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
Study: NCT01244490
Drug: Atomoxetine Hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
Study: NCT02763969
Drug: BMS-986202
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02763969
Drug: Interferon alpha-2a recombinant
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02763969
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02763969
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02562118
Drug: Lenvatinib + Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
Study: NCT03587363
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
Study: NCT01466543
Drug: Zydena (Udenafil)
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zydena (Udenafil) 100 mg, one time
Study: NCT02960893
Drug: Troriluzole
Normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
Study: NCT02960893
Drug: Troriluzole
Normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
Study: NCT02795780
Drug: Flortaucipir F18
Normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 megabecquerel (MBq) IV single-dose
Study: NCT00954252
Drug: CHF 5074
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x, oral capsule, single dose
Study: NCT00954252
Drug: CHF 5074
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x, oral capsule, single dose
Study: NCT00954252
Drug: CHF 5074
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x, oral capsule, single dose
Study: NCT00954252
Drug: CHF 5074
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8x, oral capsule, single dose
Study: NCT00954252
Drug: CHF 5074
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16x, oral capsule, single dose
Study: NCT00954252
Drug: CHF 5074
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24x, oral capsule, single dose
Study: NCT00184171
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 9 mg
Study: NCT00184171
Drug: Bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth mixture
Study: NCT00184171
Drug: Fiber
Normalized name: fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber for control
Study: NCT00000268
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02779738
Drug: Merestinib
Normalized name: Merestinib
DrugBank: Merestinib (DB12381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00822354
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
Study: NCT00683046
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
Study: NCT00683046
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 140 mg/m2 IV on day -2.
Study: NCT00683046
Drug: Stem cells
Normalized name: Stem cells, apheresis
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell infusion on day 0.
Study: NCT00683046
Drug: Campath
Normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
Study: NCT02936479
Drug: C1-INH (Berinert)
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02655146
Drug: triptorelin 0.1
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
Study: NCT00230217
Drug: Rasburicase (SR29142)
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02655146
Drug: E2
Normalized name: PE2
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
Study: NCT02655146
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
Study: NCT02655146
Drug: triptorelin 3.75mg
Normalized name: TRIPTORELIN 3.75MG/KIT SUSP SA INJ
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
Study: NCT03268902
Drug: Nitazoxanide Oral Suspension
Normalized name: nitazoxanide Oral Suspension
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
Study: NCT01479556
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
Study: NCT00591578
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT00591578
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT01861717
Drug: lanreotide
Normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
Study: NCT03033069
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brexpiprazole oral tablets.
Study: NCT03033069
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline oral capsules.
Study: NCT03033069
Drug: Brexpiprazole Matching Placebo
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brexpiprazole matching placebo oral tablets.
Study: NCT03033069
Drug: Sertraline Matching Placebo
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline matching placebo oral capsules.
Study: NCT00591578
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT03403842
Drug: PCA Morphine
Normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of endovenous morphine with a PCA
Study: NCT01081548
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg
Study: NCT00701558
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg po daily
Study: NCT00701558
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
Study: NCT02367781
Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression.
Study: NCT02367781
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Study: NCT02367781
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
Study: NCT02367781
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
Study: NCT02973633
Drug: Gadolinium DOTA Meglumine
Normalized name: gadolinium
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late Gadolinium enhancement
Study: NCT01903213
Drug: bixalomer
Normalized name: Bixalomer
DrugBank: Bixalomer (DB15200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02842086
Drug: F/TAF
Normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200/25 mg tablet administered orally once daily
Study: NCT02842086
Drug: F/TDF
Normalized name: Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200/300 mg tablet administered orally once daily
Study: NCT04071457
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Commercially available intervention
Study: NCT04071457
Drug: Daratumumab/rHuPH20
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SWOG-Held IND
Study: NCT03920527
Drug: Itraconazole 400 mg
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration of itraconazole
Study: NCT03558607
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months.
Study: NCT00418509
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00418509
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03208218
Drug: Revlimid cap
Normalized name: lenalidomide Oral Capsule [Revlimid]
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
Study: NCT02955394
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
Study: NCT02955394
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
Study: NCT03072329
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no